Fig. 4: CK666-treated BM-DCs induce more CD8+ T-cell proliferation in vivo. | British Journal of Cancer

Fig. 4: CK666-treated BM-DCs induce more CD8+ T-cell proliferation in vivo.

From: Increased cross-presentation by dendritic cells and enhanced anti-tumour therapy using the Arp2/3 inhibitor CK666

Fig. 4

a Experimental model of BM-DC migration; representative plots of CD45.1 BM-DCs detection on CD45.2 host mice and quantification of CD45.1 migratory CK666-treated (pink) or non-treated (black) BM-DCs. Results represent pooled data from 3 different experiments. Each dot represents one animal. b Experimental model of CD8+ OT-1 T-cell proliferation in vivo; representative plots of CFSE-labelled CD8+ OT-1 T-cell proliferation after primed by BM-DCs and quantification of CD8+ OT-1 T cells that proliferated after being activated by CK666-treated or non-treated BM-DCs in vivo. Results represent pooled data from 3 different experiments. Each dot represents one animal. Graphs show mean values ± SD and significance was assessed by two-way ANOVA with multiple comparisons. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.

Back to article page